Clinical trials: Stage III Lung Non-Small Cell Cancer AJCC v7
Stage III Non-small-cell Lung Cancer
A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
Stage III non-small-cell lung cancer (NSCLC) is seen in a relatively heterogeneous group of patients with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of different treatment modalities are not clear.
- Trial name
- NCT04181372
- Testing
- Anlotinib hydrochloride, platinum-based chemotherapy medicine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Non-small Cell Lung Cancer
Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC
In patients with locally advanced stage III non-small cell lung cancer, the probability of local control remains low (about 17% at 1 year). Concomitant radio-chemotherapy is the standard treatment.
- Trial name
- RTEP7 (NCT02473133)
- Testing
- Personalized dose redistribution, No personalized dose redistribution
- Where
- France
- Volunteers
- 158 people
- Sponsor
- Centre Henri Becquerel
Non Small Cell Lung Cancer
Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer
This is an open-label, single-arm, phase II, multi-center clinical trial. Thirty patients will be enrolled in this trial to investigate the pathological complete response rate defined as the absence of residual tumor in lung and…
- Trial name
- NeoTAP01 (NCT04304248)
- Testing
- Albumin-bound paclitaxel, Carboplatin, Toripalimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hao Long
Lymphoma, Metastatic Malignant Solid Neoplasm
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or…
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer
- Trial name
- NCT03229278
- Testing
- Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey
Non Small Cell Lung Cancer
Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant Durvalumab/Anlotinib/Chemotherapy followed by surgery in resectable stage III non-small cell lung cancer.
- Trial name
- NCT04762030
- Testing
- Durvalumab Anlotinib Carboplatin Nab-paclitaxel
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
NSCLC Stage III, SHR-1701
SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer
This randomized phase II exploratory clinical study aims to evaluate the efficacy and safety of SHR-1701 in patients with unresectable stage III non-small cell lung cancer (NSCLC).
- Conditions
- NSCLC Stage III, SHR-1701, Chemoradiotherapy
- Trial name
- NCT07619911
- Testing
- SHR-1701 combined with platinum-doublet chemotherapy induction therapy, SHR-1701 consolidation therapy, Platinum-doublet chemotherapy
- Volunteers
- 84 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer Stage III Unresectable
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
The reference treatment for locally advanced (stage III) non-small cell lung cancer (NSCLC) is concomitant chemoradiotherapy (CRT) followed by durvalumab consolidation for 1 year.
- Trial name
- IDEATION (NCT07759492)
- Testing
- CAPP-Seq technique, Durvalumab
- Where
- 32 sites in France
- Volunteers
- 177 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery.
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma
- Trial name
- NCT00334815
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 61 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer(NSCLC) is the leading cause of death in Korean men after stomach cancer. Surgical resection plays a main role for curative treatment.
- Trial name
- NCT00326378
- Testing
- consolidation chemotherapy with Docetaxel plus cisplatin, CCRT arm without consolidation chemotherapy
- Where
- South Korea
- Volunteers
- 434 people
- Sponsor
- Samsung Medical Center
Non-Small Cell Lung Cancer
Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
In a previous phase II study, patients with pathological stage IIIb (without pleural effusion) NSCLC were treated with concurrent cisplatin and etoposide plus thoracic radiotherapy followed by 3 cycles of consolidation therapy…
- Trial name
- NCT00216125
- Testing
- Cisplatin, Etoposide, Radiation
- Where
- 15 sites in United States
- Volunteers
- 243 people
- Sponsor
- Nasser Hanna, M.D.
Non Small Cell Lung Cancer
DE-CT in Lung Cancer Proton Therapy
Dose distribution calculations for proton therapy are more accurate when based on DE-CT than on SE-CT. It is however unclear what the quantitative benefit of repeated DE-CT calculations is for lung cancer patients.
- Trial name
- DE-CT (NCT02844140)
- Testing
- DE-CT's and SE-CT
- Where
- Netherlands
- Sponsor
- Maastricht Radiation Oncology
Lung Cancer
Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, pemetrexed disodium, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00301808
- Testing
- Cisplatin, Docetaxel, Pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Stage III NSCLC
Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)
This is a multi-center, open-label, randomized Phase 2 trial evaluating PDR001 in two arms for concurrent chemoradiation and consolidation in the treatment-naïve patients with locally advanced, unresectable stage III NSCLC.
- Trial name
- NCT03945227
- Testing
- standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001, PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001
- Where
- South Korea
- Sponsor
- Yonsei University
Stage III Non-small-cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre.
- Conditions
- Stage III Non-small-cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Radiotherapy Side Effect
- Trial name
- NCT03742687
- Testing
- Heterogeneously Hypofractionated Radiotherapy
- Where
- Denmark
- Volunteers
- 151 people
- Sponsor
- Danish Lung Cancer Group
Lung Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as irinotecan, cisplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00616785
- Testing
- cisplatin, etoposide, irinotecan hydrochloride
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Yonsei University
Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
This randomized phase II trial studies how well chemotherapy and radiation therapy given with or without metformin hydrochloride works in treating patients with stage III non-small cell lung cancer.
- Conditions
- Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma
- Trial name
- NCT02186847
- Testing
- Radiation Therapy, Carboplatin, Metformin
- Where
- 223 sites in United States, Canada and 1 more
- Volunteers
- 170 people
- Sponsor
- NRG Oncology
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Adenocarcinoma AJCC v7
Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of methoxyamine when given together with pemetrexed disodium, cisplatin, and radiation therapy in treating patients with stage IIIA-IV non-small cell lung cancer.
- Conditions
- Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Adenocarcinoma AJCC v7, Stage III Lung Large Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02535325
- Testing
- 3-Dimensional Conformal Radiation Therapy, Cisplatin, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer Stage III
The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT
The present investigation constitutes a prospective cohort study. The objectives encompass the assessment of miRNA expression levels in total exosomes derived from peripheral circulation tissues of stage III definite KRT NSCLC…
- Trial name
- NCT06015815
- Where
- Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- Ankara University
Lung Cancer
Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer
RATIONALE: Determining whether erlotinib passes into the cerebrospinal fluid may help in planning treatment for some types of cancer.
- Trial name
- NCT00305617
- Testing
- antitumor drug screening assay
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Cleveland Clinic
Non-small Cell Lung Cancer Stage III
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
This is a phase II, non-randomized, open-label, multi-center study to evaluate the efficacy of neoadjuvant Sintilimab (PD-1 antibody) or combined with chemotherapy as first-line treatment in patients with stage III non-small cell…
- Trial name
- NCT04728724
- Testing
- Sintilimab, Chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China